STSA

NASDAQ

Satsuma Pharmaceuticals Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2019

$1.09-0.03 (-2.68%)

News25/Ratings2

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Latest news

25 items

1039dSEC
SEC Form 15-12G filed by Satsuma Pharmaceuticals Inc.
15-12G - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
1044dPR
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 65th Annual Scientific Meeting
DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society's (AHS) 65th Annual Scientific Meeting. The 2023 meeting will be held in a hybrid virtual and in-p
1046dINSIDER
SEC Form 4 filed by Ra Capital Management, L.P.
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1047d13D/G
SEC Form SC 13D/A filed by Satsuma Pharmaceuticals Inc. (Amendment)
SC 13D/A - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
1050dNEWS
Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Satsuma Pharmaceuticals The Trade: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) 10% owner Shin Nippon Biomedical Laboratories Ltd acquired a total 30,477,313 shares an average price of $0.91. To acquire these shares, it cost around $27.73 million. The
1050dSEC
SEC Form EFFECT filed by Satsuma Pharmaceuticals Inc.
EFFECT - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
1050dSEC
SEC Form EFFECT filed by Satsuma Pharmaceuticals Inc.
EFFECT - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
1050dSEC
SEC Form EFFECT filed by Satsuma Pharmaceuticals Inc.
EFFECT - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
1051dINSIDER
SEC Form 4 filed by O'Neil Thomas P.
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dINSIDER
SEC Form 4 filed by Shah Rajeev M.
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dINSIDER
SEC Form 4 filed by Takanashi Ken
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dINSIDER
SEC Form 4 filed by Riebe Michael T
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dINSIDER
SEC Form 4 filed by Sandoval Elisabeth
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dINSIDER
SEC Form 4 filed by Soloway Thomas P
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dINSIDER
SEC Form 4 filed by Kollins John A
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dINSIDER
SEC Form 4 filed by Lukatch Heath
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dINSIDER
SEC Form 4 filed by King Thomas Braxton
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dINSIDER
SEC Form 4 filed by Shin Nippon Biomedical Laboratories, Ltd.
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dINSIDER
SEC Form 4 filed by Harsch Mutya
4 - Satsuma Pharmaceuticals, Inc. (0001692830) (Issuer)
1051dSEC
SEC Form 25-NSE filed by Satsuma Pharmaceuticals Inc.
25-NSE - Satsuma Pharmaceuticals, Inc. (0001692830) (Subject)
1051dSEC
SEC Form S-8 POS filed by Satsuma Pharmaceuticals Inc.
S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
1051dSEC
SEC Form S-8 POS filed by Satsuma Pharmaceuticals Inc.
S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
1051dSEC
SEC Form S-8 POS filed by Satsuma Pharmaceuticals Inc.
S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
1051dSEC
SEC Form S-8 POS filed by Satsuma Pharmaceuticals Inc.
S-8 POS - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)
1051dSEC
SEC Form POS AM filed by Satsuma Pharmaceuticals Inc.
POS AM - Satsuma Pharmaceuticals, Inc. (0001692830) (Filer)